Table 3.
Univariate and multivariate analysis for the prognostic significance of clinicopathological characteristics and serum miR-150 levels in HCC
| Parameter | Univariate analysis | Multivariate analysisa | ||
|---|---|---|---|---|
| HR (95 % CI)b | P-value | HR (95 % CI)b | P-value | |
| Genderc | 0.638 (0.358–1.136) | 0.127 | ||
| Agec | 0.892 (0.520–1.528) | 0.677 | ||
| AFPc | 1.693 (0.903–3.173) | 0.095 | ||
| Tumor diameterc | 1.567 (0.909–2.703) | 0.106 | ||
| Differentiationc | 1.560 (0.908–2.679) | 0.107 | ||
| BCLC stagesc | 3.284 (1.830–5.540) | <0.001d | 2.631 (1.309–5.286) | 0.006d |
| TNM stagesc | 3.133 (1.803–5.444) | <0.001d | 2.180 (1.129–4.210) | 0.020d |
| miR-150 | 0.329 (0.189–0.571) | <0.001d | 0.446 (0.233–0.854) | 0.015d |
aBackward Wald test used for variables screened, P = 0.05 was chosen as a criteria for significance; bCI, 95 % confidence interval; cgender, male vs. female; age, ≥60 vs. <60 years; AFP, ≥20 vs. <20 ng/ml; tumor diameter, ≥5 vs. <5 cm; differentiation, poor vs. moderate and well; BCLC stage, B vs. A; TNM stage, III vs. I and II; d P < 0.05